Taken together, this simplified pathological model builds the basis of the current A-T-N classification of AD, which aims to integrate three biomarkers (amyloidosis, tau, neurodegeneration) into the diagnostic research protocol, facilitating a uniform quantification independent of clinical symptoms (Jack et al., 2018). The gene discussed is MAPT; the disease is amyloidosis.